(Colorectal Cancer) Is Adagrasib ± Cetuximab Effective? KRYSTAL-1 Phase 1/2 Trial Results
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- February 1, 2023
- 1 min read
On December 21, 2022, Rona Yaeger and colleagues from Memorial Sloan Kettering Cancer Center published results in the New England Journal of Medicine from the KRYSTAL-1 Phase 1/2 clinical trial evaluating the efficacy and safety of adagrasib ± cetuximab in previously treated KRAS G12C mutation-positive metastatic colorectal cancer patients.
Trial Design:
The KRYSTAL-1 trial was an open-label, non-randomized study enrolling previously treated KRAS G12C mutation-positive metastatic colorectal cancer patients (N=76), divided into:
- Adagrasib monotherapy group: 600 mg twice daily (N=44)
- Adagrasib 600 mg twice daily + cetuximab 250 mg/m² weekly or 500 mg/m² biweekly (N=32)
Primary endpoints were objective response rate (ORR) and safety.
Results at median follow-up of 20.1 months (monotherapy) and 17.5 months (combination):
| Endpoint | Adagrasib alone | Adagrasib + Cetuximab |
|---|---|---|
| ORR | 19% | 46% |
| Median duration of response | 4.3 months | 7.6 months |
| Median PFS | 5.6 months | 6.9 months |
Safety:
Grade 3–4 adverse events: Adagrasib alone 34% vs. adagrasib + cetuximab 16%.
Conclusion: Based on the KRYSTAL-1 trial results, Rona Yaeger and colleagues concluded that adagrasib ± cetuximab demonstrated favorable anti-tumor activity in previously treated KRAS G12C-mutant metastatic colorectal cancer patients, with the combination showing a duration of response exceeding 6 months.
Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2212419
Colorectal Cancer | KRAS G12C | Adagrasib | Cetuximab
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4